Nanoportal Biotech Unveils Groundbreaking EASY Platform at ASGCT 2025
At the recently concluded 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Nanoportal Biotech made a stunning debut with the world’s first EASY platform (the first mammalian coacervate-based delivery platform). This pioneering gene delivery technology drew global attention and demonstrated China’s breakthrough innovation in the field. Link to the published oral presentation and poster abstract:The First Coacervate-based Delivery System for Advanced Gene Therapy
A Technological Breakthrough: Showcasing “Intelligent Manufacturing in China”
Nanoportal Biotech's EASY delivery platform became a major highlight at the conference, thanks to its remarkable advantages:
Non-viral, non-electroporation, non-lipid-based: The world's first endogenous protein coacervate-based non-viral delivery system
Ultra-high loading capacity: Delivers nucleic acids with a payload approximately 50 times greater than that of lipid nanoparticles (LNPs)
Broad nucleic acid compatibility: Capable of delivering pDNA, mRNA, siRNA, sgRNA, Cas9 mRNA, and Cas9 protein
High efficiency with low toxicity: Achieves equal or better delivery efficiency compared to traditional electroporation methods, while significantly reducing cell death and ensuring greater cell viability
Broad cell type applicability: Effectively delivers genes into various primary cells, including NK cells, B cells, and hematopoietic stem cells
Global Recognition: High Praise from Leading Experts
During the conference, we engaged in in-depth discussions with scholars from world-renowned research institutions and cutting-edge biotech companies.
We are deeply grateful for the attention and feedback from all participating experts. Nanoportal Biotech will continue to push boundaries in gene delivery innovation and remain committed to providing superior solutions for researchers around the world.
